...
首页> 外文期刊>Journal of applied toxicology >Test battery with the human cell line activation test, direct peptide reactivity assay and DEREK based on a 139 chemical data set for predicting skin sensitizing potential and potency of chemicals
【24h】

Test battery with the human cell line activation test, direct peptide reactivity assay and DEREK based on a 139 chemical data set for predicting skin sensitizing potential and potency of chemicals

机译:基于139种化学数据集的人体细胞系激活测试,直接肽反应性测定和DEREK来测试电池,以预测皮肤致敏潜力和化学功效

获取原文
获取原文并翻译 | 示例
           

摘要

To develop a testing strategy incorporating the human cell line activation test (h-CLAT), direct peptide reactivity assay (DPRA) and DEREK, we created an expanded data set of 139 chemicals (102 sensitizers and 37 non-sensitizers) by combining the existing data set of 101 chemicals through the collaborative projects of Japan Cosmetic Industry Association. Of the additional 38 chemicals, 15 chemicals with relatively low water solubility (log Kow > 3.5) were selected to clarify the limitation of testing strategies regarding the lipophilic chemicals. Predictivities of the h-CLAT, DPRA and DEREK, and the combinations thereof were evaluated by comparison to results of the local lymph node assay. When evaluating 139 chemicals using combinations of three methods based on integrated testing strategy (ITS) concept (ITS-based test battery) and a sequential testing strategy (STS) weighing the predictive performance of the h-CLAT and DPRA, overall similar predictivities were found as before on the 101 chemical data set. An analysis of false negative chemicals suggested a major limitation of our strategies was the testing of low water-soluble chemicals. When excluded the negative results for chemicals with log Kow > 3.5, the sensitivity and accuracy of ITS improved to 97% (91 of 94 chemicals) and 89% (114 of 128). Likewise, the sensitivity and accuracy of STS to 98% (92 of 94) and 85% (111 of 129). Moreover, the ITS and STS also showed good correlation with local lymph node assay on three potency classifications, yielding accuracies of 74% (ITS) and 73% (STS). Thus, the inclusion of log Kow in analysis could give both strategies a higher predictive performance. Copyright (c) 2015 John Wiley & Sons, Ltd.
机译:为了制定将人类细胞系激活测试(h-CLAT),直接肽反应性测试(DPRA)和DEREK结合在一起的测试策略,我们通过结合现有技术创建了139种化学物质(102种敏化剂和37种非敏化剂)的扩展数据集通过日本化妆品工业协会的合作项目获得的101种化学品的数据集。在另外38种化学药品中,选择了15种水溶性相对较低(log Kow> 3.5)的化学药品来阐明亲脂性化学药品测试策略的局限性。 h-CLAT,DPRA和DEREK及其组合的预测性通过与局部淋巴结试验的结果进行比较来评估。当使用基于综合测试策略(ITS)概念(基于ITS的测试电池)和权衡h-CLAT和DPRA的预测性能的顺序测试策略(STS)三种方法的组合评估139种化学品时,发现总体上具有相似的可预测性和以前一样,在101化学数据集上。对假阴性化学物质的分析表明,我们策略的主要局限性在于测试低水溶性化学物质。如果排除log Kow> 3.5的化学药品的阴性结果,则ITS的灵敏度和准确性分别提高到97%(94种化学药品中的91种)和89%(128种化学药品中的114种)。同样,STS的灵敏度和准确度分别为98%(94个中的92个)和85%(129个中的111个)。此外,ITS和STS在三个效价分类上也与局部淋巴结测定法显示出良好的相关性,产生的准确度分别为74%(ITS)和73%(STS)。因此,在分析中包含log Kow可以使两种策略具有更高的预测性能。版权所有(c)2015 John Wiley&Sons,Ltd.

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号